DCOY.US Decoy Therapeutics Inc.
- Market cap
- USD 2.33M
- P/E
- 0.1x
- P/B
- 0.16x
- ROE
- -212.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is DCOY.US undervalued?
Graham numberThe Graham number of Decoy Therapeutics Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Decoy Therapeutics Inc. fundamental analysis
No fundamental analysis for Decoy Therapeutics Inc. yet.
Decoy Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Decoy Therapeutics Inc.
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniq…
Full company profileDecoy Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Decoy Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.01M | 1.27M | 838K | 3.47M | 5.23M | 1.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 348K | 768K | 407K | 3.47M | 5.23M | 1.82M | -6.68K | -10.1K | -4.42K | -8.52M | - |
| Operating Income | -39.9M | -34.7M | -22.1M | -8.27M | -7.79M | -12.8M | -31.8M | -12.9M | -5.73M | -12.6M | -9.83M |
| EBITDA | -39.6M | -34.4M | -21.8M | -8.14M | -7.59M | -12.7M | -23.0M | -12.5M | -5.57M | -12.5M | -9.16M |
| Net Income | -39.5M | -34.4M | -21.9M | -6.94M | -7.35M | -12.8M | -31.6M | -12.5M | -5.58M | -12.5M | -9.20M |
| EPS | -182,839 | -149,712 | -1,043,915 | -6,369 | -1,416 | -926 | -1,785 | -461 | -87 | -26 | -17 |
| Balance Sheet | |||||||||||
| Total Assets | 63.2M | 35.0M | 10.4M | 13.9M | 24.9M | 40.8M | 14.7M | 6.59M | 3.02M | 11.1M | 9.00M |
| Total Liabilities | 3.90M | 5.89M | 1.11M | 3.31M | 2.77M | 2.11M | 4.27M | 1.30M | 1.51M | 5.17M | 4.68M |
| Shareholders' Equity | 59.3M | 29.1M | 9.28M | 10.6M | 22.2M | 38.7M | 10.4M | 5.29M | 1.51M | 5.89M | 4.32M |
| Cash & Short-term Investments | 61.1M | 33.3M | 9.83M | 3.74M | 11.1M | 29.2M | 12.1M | 5.90M | 2.43M | 10.7M | 8.29M |
| Total Debt | - | - | - | 502K | 477K | - | - | 290K | 222K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -32.1M | -27.7M | -23.6M | -11.6M | -10.3M | -10.2M | -17.6M | -12.8M | -4.53M | -4.83M | -11.1M |
| Capital Expenditure | 559K | 113K | 0.00 | 4.00 | 2.60K | 3.00 | 1.50M | 3.00 | 3.00 | 577K | 84.8K |
| Free Cash Flow | -32.6M | -27.8M | -23.6M | -11.6M | -10.3M | -10.2M | -19.1M | -12.8M | -4.53M | -4.83M | -11.2M |
| Ratios | |||||||||||
| ROE | -66.6% | -118.3% | -236.2% | -65.6% | -33.2% | -33.0% | -304.4% | -237.2% | -368.8% | -212.6% | -212.8% |
| ROA | -62.5% | -98.4% | -211.0% | -49.9% | -29.5% | -31.3% | -215.7% | -190.4% | -184.4% | -113.2% | -102.2% |
| Net Profit Margin | -3,907.6% | -2,701.7% | -2,615.6% | -200.2% | -140.5% | -693.8% | - | - | - | - | - |
| Debt to Equity | - | - | - | 0.05x | 0.02x | - | - | 0.05x | 0.15x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Decoy Therapeutics Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 134K | 123 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:12 on Mar 9, 2026.
Who owns Decoy Therapeutics Inc.
- Insiders 2.87%
- Institutions 4.20%
- Public & others 92.94%
- Shares outstanding 2.39M
- Free float 586K
Top funds holding DCOY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 7.61K | 1.29% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 477.00 | 0.08% | 0.00% | Sep 2026 |
| Horizon Kinetics Medical ETF | 20.00 | 0.00% | 0.00% | Oct 2026 |
Top institutions holding DCOY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 4.03K | 0.17% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 256.00 | 0.01% | -74.93% | Jun 2026 |
| UBS Group AG | 25.00 | 0.00% | -95.42% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Advisory Services Network, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Decoy Therapeutics Inc. company profile
- Company name
- Decoy Therapeutics Inc.
- Ticker
- DCOY.US
- Exchange
- USA Stocks
- Listed since
- Jan 7, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Fiscal year end
- December
- Address
- 2450 Holcombe Blvd, Houston, TX, United States, 77021
- Phone
- 713 913 5608
- Website
- decoytx.com
About Decoy Therapeutics Inc.
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.
Decoy Therapeutics Inc. management
4- Mr. Frederick E. Pierce IICEO & Director · born 1962
- Dr. Barbara Hibner Ph.D.Co-Founder & Chief Scientific Officer · born 1962
- Mr. Mark J. Rosenblum CPAExecutive VP of Finance & CFO · born 1953
- Mr. Peter K. Marschel M.B.A., M.S.Chief Business Officer · born 1975